Ray Dalio’s Denali Therapeutics DNLI Stock Holding History

Ray Dalio’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,970	Closed	-$416K	–	770
2022 Q4	$416K	Buy	+14,970	New	+$445K	﹤0.01%	738
2022 Q3	–	Sell	-8,660	Closed	-$255K	–	906
2022 Q2	$255K	Buy	8,660 +1,793	+26%	+$47K	﹤0.01%	957
2022 Q1	$221K	Buy	+6,867	New	+$236K	﹤0.01%	955

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Ray Dalio's DNLI Position: Q1 2023 in Review

Ray Dalio sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 14,970 shares — an estimated $416K sold.

Ray Dalio first reported a position in DNLI in Q1 2022 and held it in 3 quarters. The position peaked at $416K in Q4 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

Ray Dalio reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
Ray Dalio sold 14,970 Denali Therapeutics shares in Q1 2023, an estimated $416K.
Ray Dalio first reported a position in Denali Therapeutics in Q1 2022 and held it in 3 quarters.
Ray Dalio's Denali Therapeutics position peaked at $416K in Q4 2022.
202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Bridgewater Associates's 13F filing for Q1 2023, filed 12 May 2023.